Search Result

Results for "

FKBP12

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Antibiotic (3) Apoptosis (5) AUTACs (2) Autophagy (11) Bacterial (4) Calcium Channel (1) E3 Ligase Ligand-Linker Conjugates (2) Endogenous Metabolite (2) Epigenetic Reader Domain (2) FKBP (29) Fungal (3) Isotope-Labeled Compounds (1) Ligands for E3 Ligase (1) Ligands for Target Protein for PROTAC (6) mTOR (8) Parasite (1) PROTACs (13)
By Research Areas:	Cancer (35) Infection (1) Inflammation/Immunology (3) Neurological Disease (2)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114421

FKBP12 PROTAC dTAG-13 2 Publications Verification dTAG-13	PROTACs FKBP	Cancer
FKBP12 PROTAC dTAG-13 (dTAG-13), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 ^F36V with expression of FKBP12F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-13 effectively engages FKBP12 ^F36V and CRBN, thereby selectively degrading FKBP12 ^F36V .

HY-130835

FKBP12 PROTAC RC32 RC32	PROTACs FKBP	Cancer
FKBP12 PROTAC RC32 (RC32) is a potent *FKBP12* degrader based on PROTAC technology. FKBP12 PROTAC RC32 contains conjugation of Rapamycin (HY-10219) and a ligand for an Cereblon E3 ubiquitin ligase (Pomalidomide; HY-10984) .

HY-123941

FKBP12 PROTAC dTAG-7 1 Publications Verification dTAG-7	PROTACs FKBP Epigenetic Reader Domain	Cancer
FKBP12 PROTAC dTAG-7 (dTAG-7) is a heterobifunctional degrader. FKBP12 PROTAC dTAG-7 (dTAG-7) is a degrader of FKBP12 ^F36V with expression of FKBP12 ^F36V in-frame with a protein of interest. FKBP12 PROTAC dTAG-7 (dTAG-7) also is a selective degrader of BET bromodomain transcriptional co-activator BRD4 by bridging BET bromodomains to an E3 ubiquitin ligase CRBN .

HY-107452

SLF-amido-C2-COOH PROTAC FKBP12-binding moiety 1	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) is a synthetic ligand for *FKBP* (SLF). SLF-amido-C2-COOH (PROTAC FKBP12-binding moiety 1) can be used in the synthesis of PROTACs .

HY-153806

RapaBlock ZZY05-092	FKBP	Cancer
RapaBlock is a potent, non-immunosuppressive and brain-impermeable *FKBP12* ligand .

HY-103634

dFKBP-1 1 Publications Verification	PROTACs FKBP	Cancer
dFKBP-1 is a potent and PROTAC-based *FKBP12* degrader. dFKBP-1 incorporates the ligand SLF (HY-114872) of *FKBP12, the Thalidomide based Cereblon* ligand and a linker .

HY-147098

dTAG-47	PROTACs FKBP	Cancer
dTAG-47, heterobifunctional dTAG molecule, targets mutant FKBP12 (FKBP12 ^F36V). FKBP12 ^F36V serves as a degradation tag (dTAG) and is fused to a protein of interest. dTAG-47 can be used for the research of basal-like breast cancers (BBC) .

HY-145514C

dTAGV-1 hydrochloride	FKBP PROTACs	Cancer
dTAGV-1 hydrochloride is the hydrochloride form of dTAGV-1 that is a small molecule degrader of *FKBP12* .

HY-114420

AP1867-2-(carboxymethoxy) PROTAC FKBP12-binding moiety 2	FKBP Ligands for Target Protein for PROTAC	Cancer
AP1867-2-(carboxymethoxy), the AP1867 (a synthetic FKBP12 ^F36V-directed ligand) based moiety, binds to CRBN ligand via a linker to form dTAG molecules .

HY-161794

SP3N	FKBP Ligands for Target Protein for PROTAC	Cancer
SP3N is a specific degrader of the prolyl isomerase *FKBP12. The alkylamine of SP3N is metabolized to a reactive aldehyde (SP3CHO), which recruits the SCFFBXO22 ligase for FKBP12* degradation. SP3N may be used in research for cancer .

HY-169148

YT117R	PROTACs FKBP Epigenetic Reader Domain	Cancer
YT117R is a PROTAC degrader of *FKBP12* and Pink: Target protein ligand: (HY-158301); Black: linker (HY-42776); Blue: E3 ligase ligand (HY-78695)) .

HY-134184

AUTAC2	AUTACs Autophagy	Inflammation/Immunology Cancer
AUTAC2 is a *FKBP12*-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG (p-Fluorobenzyl Guanine) and an SLF (c ligand of FKBP) moiety. SLF binds non-covalently to FKBP12 .

HY-10219

Rapamycin Maximum Cited Publications 850 Publications Verification Sirolimus; AY-22989	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-114872

SLF	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for *FKBP51* and an IC₅₀ of 2.6 μM for *FKBP12*. SLF can be used in the synthesis of PROTAC .

HY-131344

mTOR inhibitor-8	mTOR Autophagy	Cancer
mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .

HY-145514

dTAGV-1 TFA	PROTACs	Cancer
dTAGV-1 TFA is a potent and selective degrader of mutant FKBP12 ^F36V fusion proteins. dTAGV-1 TFA can induce degradation of FKBP12 ^F36V-Nluc in vivo .

HY-114872A

SLF TFA	Ligands for Target Protein for PROTAC FKBP	Cancer
SLF TFA is a synthetic ligand for FK506-binding protein (FKBP) with an affinity of 3.1 μM for *FKBP51* and an IC₅₀ of 2.6 μM for *FKBP12*. SLF TFA can be used in the synthesis of PROTAC .

HY-10219S

Rapamycin-d3 Sirolimus-d₃; AY-22989-d₃	mTOR FKBP Autophagy	Cancer
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-114434

AP1867 2 Publications Verification	FKBP	Cancer
AP1867 is a synthetic FKBP12 ^F36V-directed ligand .

HY-10219R

Rapamycin (Standard)	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial	Cancer
Rapamycin (Standard) is the analytical standard of Rapamycin. This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-129610

KB02-SLF	PROTACs FKBP	Cancer
KB02-SLF is a PROTAC-based nuclear *FKBP12* degrader (molecular glue). KB02-SLF promotes nuclear *FKBP12* degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. SLF binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-SLF .

HY-145514A

dTAGV-1-NEG	PROTACs FKBP	Cancer
dTAGV-1-NEG is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1 is an FKBP12 ^F36V-selective degrader .

HY-161157

dTAG-13-NEG	PROTACs	Cancer
dTAG-13-NEG is a negative control of dTAG-13. dTAG-13 (HY-114421), a PROTAC-based heterobifunctional degrader, is a selective degrader of FKBP12 ^F36V with expression of FKBP12F36V in-frame with a protein of interest .

HY-10218

Everolimus 80+ Cited Publications RAD001; SDZ-RAD	mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to *FKBP-12* to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-150410

TSPO ligand-3	AUTACs	Cancer
TSPO ligand-3 is a ligand of AUTAC2. AUTAC2 contains an p-fluorobenzylguanine (FBnG) and an synthetic ligand of FKBP (SLF) moiety, which can cause significant silencing of FKBP12 in HeLa cells .

HY-145514B

dTAGV-1-NEG TFA	PROTACs FKBP	Cancer
dTAGV-1-NEG TFA is a diastereomer and as a heterobifunctional negative control of dTAGV-1. dTAGV-1-NEG TFA is an FKBP12 ^F36V-selective degrader .

HY-10218S

Everolimus-d4 RAD001-d₄; SDZ-RAD-d₄	mTOR FKBP Autophagy Apoptosis	Cancer
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

HY-129363

AP1867-3-(aminoethoxy)	Ligands for Target Protein for PROTAC FKBP	Cancer
AP1867-3-(aminoethoxy), the AP1867 based moiety, is a synthetic ligand for *FKBP. AP1867-3-(aminoethoxy) can be used in the synthesis of PROTAC FKBP12* F36V degrader .

HY-135250B

Thalidomide-4-O-C6-NH2 hydrochloride	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-4-O-C6-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13, a degrader of FKBP12 ^F36V and BET .

HY-112210

Shield-1 4 Publications Verification Shld1	FKBP	Others
Shield-1 (Shld1) is a specific, cell-permeant and high-affinity ligand of FK506-binding protein-12 (FKBP), and reverses the instability by binding to *mutated FKBP* (mtFKBP)*, allowing conditional expression of mtFKBP-fused proteins. Shield-1 can stabilize proteins tagged with a mutated FKBP12*-derived destabilization domain (DD) .

HY-10218R

Everolimus (Standard) RAD001 (Standard); SDZ-RAD (Standard)	mTOR FKBP Autophagy Apoptosis Bacterial	Cancer
Everolimus (Standard) is the analytical standard of Everolimus. This product is intended for research and analytical applications. Everolimus (RAD001) is a Rapamycin (HY-10219) derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to *FKBP-12* to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities .

HY-135250A

Thalidomide-4-O-C6-NH2 TFA	E3 Ligase Ligand-Linker Conjugates Autophagy Apoptosis	Cancer
Thalidomide-4-O-C6-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate used in the PROTAC dTAG-13 (HY-114421), a degrader of FKBP12 ^F36V and BET .

HY-106345

ILS-920	FKBP Calcium Channel	Neurological Disease Inflammation/Immunology
ILS-920 is a nonimmunosuppressive Rapamycin analog with reduced immunosuppressive activity and potent neuroprotective activity. ILS-920 binds selectively to the immunophilin *FKBP52* and to the β1-subunit of L-type voltage-gated calcium channels (VGCC). ILS-920 shows 200-fold selectivity for *FKBP52* versus FKBP12 .

HY-169147

MY-11B	Ligands for E3 Ligase	Cancer
MY-11B is a DCAF1 ligand. MY-11B shows reactivity with DCAF1_C1113. MY-11B blockes YT41R and YT47R-mediated degradation of HA-FKBP12. MY-11B can be used in the synthesis of PROTACs .

HY-10219S1

Rapamycin-13C,d3 Sirolimus-¹³C,d₃; AY-22989-¹³C,d₃	Isotope-Labeled Compounds	Others
Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-163807

22-SLF	PROTACs FKBP	Cancer
22-SLF is a PROTAC degrader, that degrades FK506-binding protein 12 (FKBP12) with a DC₅₀ of 0.5 µM in a FBXO22 dependent manner. 22-SLF degrades other endogenous proteins, such as BRD4 and EML4-ALK fusion protein.(Pink: Ligand for target protein SLF (HY-114872); Black: Linker (HY-163821); Blue: Ligand for E3 ligase (HY-163826)) .

HY-111373

RapaLink-1 5+ Cited Publications	mTOR Autophagy	Cancer
RapaLink-1, the third-generation bivalent mTOR inhibitor, combines Rapamycin (HY-10219) with MLN0128 (HY-13328, a second-generation mTOR kinase inhibitor) by an inert chemical linker. RapaLink-1 shows better efficacy than Rapamycin or mTOR kinase inhibitors (TORKi), potently blocking cancer-derived, activating mutants of mTOR. RapaLink-1 can cross the blood-brain barrier. RapaLink-1 binding to FKBP12 results in targeted and durable inhibition of mTORC1. RapaLink-1 plays an antithrombotic role in antiphospholipid syndrome by improving autophagy. Anticancer activity .

HY-145712

ElteN378	FKBP	Cancer
ElteN378 is an inhibitors of *FKBP12e*. ElteN378 can be used in study Alzheimer disease, Parkinson disease, Amyotrophic Lateral Sclerosis, proliferation disorders and cancer .

HY-13557

Ascomycin 5+ Cited Publications Immunomycin; FR-900520; FK520	FKBP Parasite Fungal Antibiotic	Infection Neurological Disease Inflammation/Immunology
Ascomycin (Immunomycin; FR-900520; FK520) is an ethyl analog of Tacrolimus (FK506) with strong immunosuppressant properties. Ascomycin is also a macrocyclic polyketide antibiotic with multiple biological activities such as anti-malarial, anti-fungal and anti-spasmodic. Ascomycin prevents graft rejection and has potential for varying skin ailments research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-10219

Rapamycin 845+ Cited Publications Sirolimus; AY-22989	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Classification of Application Fields Antibiotics Anti-aging Source classification Disease Research Disease Research Fields Cancer	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-10219R

Rapamycin (Standard)	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Macrolide Antibiotics Antibiotics Source classification Disease Research Endogenous metabolite	mTOR FKBP Fungal Autophagy Endogenous Metabolite Antibiotic Bacterial
Rapamycin (Standard) is the analytical standard of Rapamycin. This product is intended for research and analytical applications. Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

HY-13557

Ascomycin 5+ Cited Publications Immunomycin; FR-900520; FK520	Structural Classification Microorganisms Anti-inflammation/Immunoregulatory Antifungal Macrolide Antibiotics Neurological Disease Classification of Application Fields Antibiotics Source classification Disease Research Inflammation/Immunology Disease Research Fields	FKBP Parasite Fungal Antibiotic
Ascomycin (Immunomycin; FR-900520; FK520) is an ethyl analog of Tacrolimus (FK506) with strong immunosuppressant properties. Ascomycin is also a macrocyclic polyketide antibiotic with multiple biological activities such as anti-malarial, anti-fungal and anti-spasmodic. Ascomycin prevents graft rejection and has potential for varying skin ailments research .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P76345

	FKBP12 Protein, Human (His) Peptidyl-prolyl cis-trans isomerase FKBP1A; FKBP-12; Calstabin-1; FKBP-1A; FKBP1	Human	E. coli
	FKBP12 protein maintains TGFBR1 in an inactive state, inhibits activin signaling by recruiting SMAD7, and modulates RYR1 calcium channel activity. As a PPIase, it speeds up protein folding. FKBP12's multifunctionality underscores its regulatory role in cellular processes, emphasizing its importance in signaling and protein folding. FKBP12 Protein, Human (His) is the recombinant human-derived FKBP12 protein, expressed by E. coli , with C-His labeled tag.

HY-P76346

	FKBP12 Protein, Mouse (His) Peptidyl-prolyl cis-trans isomerase FKBP1A; FKBP-12; Calstabin-1; FKBP-1A; FKBP1	Mouse	E. coli
	The FKBP12 protein is multifunctional and critical in TGF-β signaling by maintaining TGFBR1 in an inactive conformation, thereby preventing receptor activation in the absence of ligand. It recruits SMAD7 to ACVR1B, blocks the binding of SMAD2 and SMAD3 to the activin receptor complex, and thereby inhibits activin signaling. FKBP12 Protein, Mouse (His) is the recombinant mouse-derived FKBP12 protein, expressed by E. coli , with N-His labeled tag. The total length of FKBP12 Protein, Mouse (His) is 107 a.a., with molecular weight of ~13 KDa.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-10219S

Rapamycin-d3
Rapamycin-d₃ is the deuterium labeled Rapamycin. Rapamycin is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant .

HY-10218S

Everolimus-d4
Everolimus-d₄ is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities[1][2].

HY-10219S1

Rapamycin-13C,d3

Rapamycin- ¹³C,d₃ (Sirolimus- ¹³C,d₃; AY-22989- ¹³C,d₃) is the ¹³C and deuterium labeled Rapamycin (HY-10219) . Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC₅₀ of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1 . Rapamycin is an autophagy activator, an immunosuppressant .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80400

	FKBP12 Antibody	WB, ICC/IF	Human, Mouse
	FKBP12 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 12 kDa, targeting to FKBP12. It can be used for WB,ICC/IF assays with tag free, in the background of Human, Mouse.

HY-P80759

	mTOR Antibody MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic tar	WB, IHC-P, ICC/IF, IP, FC	Human, Mouse, Rat
	mTOR Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 289 kDa, targeting to mTOR. It can be used for WB,IHC-P,ICC/IF,IP,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80838

	Phospho-mTOR (Ser2481) Antibody MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic tar	WB	Human, Mouse, Rat
	Phospho-mTOR (Ser2481) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 289 kDa, targeting to Phospho-mTOR (Ser2481). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

HY-P80837

	Phospho-mTOR (Ser2448) Antibody (YA171) MTOR; FRAP; FRAP1; FRAP2; RAFT1; RAPT1; Serine/threonine-protein kinase mTOR; FK506-binding protein 12-rapamycin complex-associated protein 1; FKBP12-rapamycin complex-associated protein; Mammalian target of rapamycin; mTOR; Mechanistic tar	WB, IHC-P	Human, Mouse
	Phospho-mTOR (Ser2448) Antibody (YA171) is a non-conjugated and Rabbit origined monoclonal antibody about 289 kDa, targeting to Phospho-mTOR (Ser2448). It can be used for WB,IHC-P assays with tag free, in the background of Human, Mouse.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks